Interested in participating in a clinical research trial?

Fill out our quick Pre-Screening Questionnaire below

Active clinical research trials

Clinical research trials available to participants

Clinical research trials and those who contribute play a role in the development of new treatments for some of our most common and debilitating diseases and conditions.

Patients who participate in Excell’s research studies have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of psychiatric or medical conditions.

We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating.

Financial compensation may be available to those who qualify and complete visits for clinical trials at Excell.

Sign up for clinical research trial today!

Depression Clinical Research Studies

Sponsor:

Alto Neuroscience

Protocol Number:

ALTO-100-201

Summary: The ALTO-100-201 study is evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential study visits.

Eligibility Criteria

Key Inclusion Criteria:

  • Symptoms of depression for at least 6 weeks prior to entering the study.
  • Willing to comply with all study assessments and procedures.
  • Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
  • Primary symptoms of post-traumatic stress disorder.
  • Clinically significant medical conditions.
  • History of substance abuse in the past 3 months.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-70

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table

Sponsor Website: https://www.altoneuroscience.com/

_____________________________________________________________________________________________

Sponsor:

Alto Neuroscience

Protocol Number:

ALTO-100-201 (Decentralized)

Summary: The ALTO-100-201 (Decentralized) study is a partially remote study evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential remote study visits.

Eligibility Criteria

Key Inclusion Criteria:

  • Symptoms of depression for at least 6 weeks prior to entering the study.
  • Willing to comply with all study assessments and procedures.
  • Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
  • Primary symptoms of post-traumatic stress disorder.
  • Clinically significant medical conditions.
  • History of substance abuse in the past 3 months.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

No

Age:

18-70

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table

Sponsor Website: https://www.altoneuroscience.com/

______________________________________________________________________________________________

Sponsor:

Alto Neuroscience

Protocol Number:

ALTO-100-201 (Decentralized)

Summary: The ALTO-100-201 (Decentralized) study is a partially remote study evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential remote study visits.

Eligibility Criteria

Key Inclusion Criteria:

  • Symptoms of depression for at least 6 weeks prior to entering the study.
  • Willing to comply with all study assessments and procedures.
  • Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
  • Primary symptoms of post-traumatic stress disorder.
  • Clinically significant medical conditions.
  • History of substance abuse in the past 3 months.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

No

Age:

18-70

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table

Sponsor Website: https://www.altoneuroscience.com/

____________________________________________________________________________________________

Sponsor:

Janssen Research & Development, LLC

Study Name:

Ventura Study

Protocol Number:

67953964MDD3001

Summary: The Ventura study is a placebo-controlled study evaluating the safety and efficacy of Aticaprant used as adjunctively treatment to an antidepressant. The Ventura study is 13 weeks with 9 study visits in Oceanside, CA.

Eligibility Criteria

Key Inclusion Criteria:

  • Current symptoms of depression.
  • Currently taking an antidepressant medication for at least 6 weeks.
  • Willing to comply with all study assessments and procedures.
  • Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
  • History of noncompliance with current antidepressant therapy.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-74

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05518149?term=67953964MDD3001&draw=2&rank=1

Sponsor Website: https://www.janssen.com/belgium/rd-janssen

______________________________________________________________________________________________

Sponsor:

Neumora Therapeutics

Protocol Number:

NMRA-335140-301

Summary: The NMRA-335140-301 study is a placebo-controlled study evaluating the safety and efficacy of NMRA-335140 in participants with current depressive symptoms. The study is 16 weeks with 11 scheduled study visits in Oceanside, CA.

Eligibility Criteria

Key Inclusion Criteria:

  • Symptoms of depression between 4 weeks to 12 months prior to study entry.
  • Willing to comply with all study assessments and procedures.
  • Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.

Key Exclusion Criteria:

  • Diagnosed with post-traumatic stress disorder, bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
  • Unwillingness to discontinue exclusionary psychiatric medications.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-65

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05518149?term=67953964MDD3001&draw=2&rank=1

Sponsor Website: https://neumoratx.com/

__________________________________________________________________________________________

Sponsor:

Axsome Therapeutics

Protocol Number:

AXS-05-MDD-401

Summary: The AXS-05-MDD-401 study is an active-controlled study of AXS-05 for the prevention of relapse of depressive symptoms. The study is initially 10 weeks with 14 visits in Oceanside, CA with the possibility of a 26-week placebo-controlled extension.

Eligibility Criteria

Key Inclusion Criteria:

  • Symptoms of depression for at least 4 weeks.
  • Willing to comply with all study assessments and procedures.
  • Low or inadequate response to at least 1 oral antidepressant medication in the current depressive episode.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
  • Active post-traumatic stress disorder symptoms in the past 3 years.
  • Low or inadequate response to 2 or more antidepressant medications in the current depressive episode.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-65

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT04019704?term=AXS-05&rank=2

Sponsor Website: https://www.axsome.com/

Generalized Anxiety Clinical Research Studies

Sponsor:

Sunovion Pharmaceuticals

Protocol Number:

SEP361-226

Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of SEP361 n adults with Generalized Anixety Disorder.

 

Eligibility Criteria:

Key Inclusion Criteria:

  • Male or female subject between 18 to 65 years of age.
  • Symptoms of Generalized Anxiety Disorder over the past 6 months.
  • Primary focus of treatment is Generalized Anxiety Disorder.

Key Exclusion Criteria:

  • Diagnosis other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
  • Previous inadequate response to more than 3 antidepressant treatments.
  • Any clinically significant unstable medical condition or any clinically significant chronic disease, that would limit the subject’s ability to complete and/or participate in the study.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 to 65

Clinicaltrials.gov Link:

https://clinicaltrials.gov/study/NCT05729373?term=SEP361-226&aggFilters=status:rec&rank=1&tab=table

Sponsor Website:

Sunovion Pharmaceuticals Inc. – New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion’s SEP-363856 for the Treatment of Schizophrenia

Schizophrenia Clinical Research Studies

Sponsor:

Neurocrine

Study Name:

Erudite Study

Protocol Number:

NBI-1065844-CIAS2023

Summary: The Erudite study is evaluating the safety, efficacy, and tolerability of Luvadaxistat in subjects with cognitive impairment associated with schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

  • Experiencing cognitive impairment with a previous diagnosis of Schizophrenia.
  • Willing to comply with all study assessments and procedures.
  • Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 2-6mg Risperidone equivalent.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
  • Current substance/alcohol abuse.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-50

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05182476?term=NBI-1065844-CIAS2023&draw=2&rank=1

Sponsor Website: https://www.neurocrine.com/

_____________________________________________________________________________________________

Sponsor:

Neurocrine

Study Name:

Journey Study

Protocol Number:

NBI-98854-ATS3019

Summary: The Journey study is evaluating the safety, efficacy, and tolerability of Valbenazine as Adjunctive or add on treatment in subjects with schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

  • Experiencing cognitive impairment with a previous diagnosis of schizophrenia.
  • Willing to comply with all study assessments and procedures.
  • Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 3-6mg Risperidone equivalent.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
  • Current substance/alcohol abuse.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 and older

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05110157?term=NBI-98854-ATS3019&draw=2&rank=1

Sponsor Website: https://www.neurocrine.com/

______________________________________________________________________________________________

Sponsor:

Reviva Pharmaceuticals

Study Name:

Recover Study

Protocol Number:

RVP-30-001

Summary: The Recover study is evaluating the safety and efficacy of Brilaroxazine (RP5063) in subjects with acute exacerbation of schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

  • Experiencing exacerbating symptoms of schizophrenia.
  • Diagnosis of schizophrenia in in the past 1-20 years.
  • Willing to comply with all study assessments and procedures.
  • Currently taking an antipsychotic medication and willing to discontinue.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
  • History of taking Clozapine.
  • Current substance/alcohol abuse.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-65

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05184335?term=RVP-30-001&rank=1&tab=table

Sponsor Website: https://revivapharma.com/

_____________________________________________________________________________________________

Sponsor:

Click Therapeutics, Inc.

Study Name:

Convoke Study

Protocol Number:

CT-155-R-001

Summary: The Convoke study is evaluating the safety and efficacy of two digital therapeutics as an adjunctive or add on treatment to patients with negative symptoms of schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

  • Experiencing exacerbating symptoms of schizophrenia.
  • Current diagnosis of schizophrenia.
  • Willing to comply with all study assessments and procedures.
  • Currently taking an antipsychotic medication.
  • Have a device with updated IOS or Android systems and an active email address.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
  • History of taking Clozapine.
  • Current substance/alcohol abuse.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 and older

Clinicaltrials.gov Link: https://clinicaltrials.gov/study/NCT05838625?term=CT-155-R001&rank=1&tab=table

Sponsor Website: https://www.clicktherapeutics.com/

______________________________________________________________________________________________

Sponsor:

Recognify Life Sciences

Study Name:

Recognify Study

Protocol Number:

C07-03-02

Summary: The Recognify study is a placebo-controlled study evaluating the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia.

Eligibility Criteria

Key Inclusion Criteria:

  • Experiencing cognitive impairment associated with schizophrenia.
  • Diagnosis of schizophrenia for at least 6 months.
  • Willing to comply with all study assessments and procedures.
  • Currently taking an antipsychotic medication for 4 weeks prior to study entry.

Key Exclusion Criteria:

  • Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
  • History of taking Clozapine.
  • Current substance/alcohol abuse.
  • Clinically significant medical conditions.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18-55

Clinicaltrials.gov Link: https://classic.clinicaltrials.gov/ct2/show/record/NCT05686239

Sponsor Website: https://www.recognify.life/

OCD Clinical Research Studies

Sponsor:

Biohaven Pharmaceuticals

Study Name:

Biohaven Study

Protocol Number:

BHV4157-302

Summary: The Biohaven study is a placebo-controlled study evaluating the safety and efficacy of Troriluzole n adults taking an SSRI to treat symptoms of obsessive-compulsive disorder.

Eligibility Criteria:

Key Inclusion Criteria:

  • Experiencing moderate to severe symptoms of obsessive-compulsive disorder in the past year.
  • Currently taking an SSRI medication for 8 weeks prior to study entry. (Zoloft, Prozac, Lexapro, Celexa, ect.)
  • Willing to stop exclusionary psychiatric medications prior to study entry.

Key Exclusion Criteria:

  • Lifetime history of bi-polar disorder, schizophrenia, borderline personality disorder or autism spectrum disorders.
  • Unwilling to discontinue exclusionary medications or comply with study procedures.
  • Any clinically significant unstable medical condition or any clinically significant chronic disease.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

18 to 65

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT04641143?term=BHV4157-302&draw=2&rank=1

Sponsor Website:

https://www.biohaven.com/

Adolescent Migraine Clinical Research Studies

Sponsor:

AbbVie

Name:

Periscope Study

Protocol Number:

3110-305-002

Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Ubrogepant in acute treatment of migraine with or without aura in children and adolescents.

Eligibility Criteria

Key Inclusion Criteria:

  • History of 1 to 14 migraine attacks per month with moderate to severe headaches in each of the 2 months prior to study entry.
  • Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.

Key Exclusion Criteria:

  • Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
  • Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

12-17

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/study/NCT05125302?term=3110-305-002&draw=2&rank=2

Sponsor Website: https://www.abbvie.com/who-we-are.html?utm_medium=psearch&utm_campaign=corprepppp_2023&utm_source=google&utm_content=igp&utm_term=brandcore&cid=ppc_CV5d23f5fe9b1d494480b4c5bdc9a98b4d&gclid=CjwKCAjw-b-kBhB-EiwA4fvKrPKcFLoo52XYUNnDKWdQW20OpCRUZU5roVmk_UOLWa

_____________________________________________________________________________________________

Sponsor:

AbbVie

Name:

Kaleidoscope Study

Protocol Number:

M21-201

Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Atogepant for the preventive treatment of episodic migraine in children and adolescence.

Eligibility Criteria

Key Inclusion Criteria:

  • History of 4 to 14 migraine attacks per month with less than 15 headache days 28 days prior to study entry.
  • Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.

Key Exclusion Criteria:

  • Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
  • Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.
  • History of migraine aura with impairment of level of consciousness, hemiplegic migraine, or retinal migraine.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

12-17

Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT05711394?term=M21-201&draw=2&rank=1

Sponsor Website: https://www.abbvie.com/who-we-are.html?utm_medium=psearch&utm_campaign=corprepppp_2023&utm_source=google&utm_content=igp&utm_term=brandcore&cid=ppc_CV5d23f5fe9b1d494480b4c5bdc9a98b4d&gclid=CjwKCAjw-b-kBhB-EiwA4fvKrPKcFLoo52XYUNnDKWdQW20OpCRUZU5roVmk_UOLWa

Alzheimer's Disease Clinical Research Studies

Sponsor:

Otsuka Pharmaceutical Development:

Name:

Aspect Study

Protocol Number:

20-AVP-786-306

Summary: The Aspect study is a placebo-controlled study evaluating the safety and efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type.

Eligibility Criteria

Key Inclusion Criteria:

  • Probable diagnosis of Dementia of the Alzheimer’s type.
  • Caregiver participation required.

Key Exclusion Criteria:

  • Dementia other than Alzheimer’s Disease.
  • Not currently in any assisted living facility.
  • No history of seizures, severe eating disorder or any condition that increases risk of seizures.
  • No hospitalization in a mental health facility or living alone.

Patient Time Reimbursed?

Yes

Patient Travel Reimbursed?

Yes

Age:

50-90

Clinicaltrials.gov Linkhttps://clinicaltrials.gov/ct2/show/NCT04408755?term=20-AVP-786-306&draw=2&rank=1

Sponsor Websitehttps://www.otsuka-us.com/

  • Quick Form to See if you Qualify
  • Full Questionaire

    I identify as:

    Do you currently have, or have you ever had, any of the following?

    How did you hear about us?*

    *Required

    https://excellresearch.com/wp-content/uploads/2023/07/Excell-Logo-New-Outlines@2x-1.png
    https://excellresearch.com/wp-content/uploads/2023/08/qtq80-VpnKce.jpeg

    Pre-screening questionnaire and your privacy

    Please be advised that by filling out the study pre-screening questionnaire, you will be asked to provide personal information, including age, gender, and your current medical condition. One of our staff will then reach out to conduct a phone-screen to see if you qualify for one of our current studies at our office location in Oceanside, CA. Your privacy is of the utmost importance to Excell Research. Your privacy will be protected and the information you provide will only be shared with those involved with the clinical research study if it is determined that you may be eligible to participate, unless you permit us to do so or except as required by law. Your information will not be sold to outside companies, nor will it be stored or collected without your direct consent.

    Many pharmaceutical companies and Excell Research are conducting these studies under the Food and Drug Administration (FDA) to learn more about new investigational drugs or treatments. Read our privacy policy to learn more about how your information will be kept private.

      What we do here is Clinical Research, we are doing FDA testing on medications; the studies will require you to take medications, are you willing to take a medication for our studies?

      The pharmaceutical companies are the ones making the rules on the study, as far as what you can or cannot have. So, to see if the study will be a good fit for you, we will need to go over several questions about your symptoms and medical history to see if you may be eligible. We are not a treatment facility. You do not have to answer any question you do not want to answer. Your information will be recorded but will only be used for this study. Are you OK with this?

      You may be given investigational medication or placebo as part of the trial. We will not know if you are taking the actual drug ingredients or something that will look like it but not have any active ingredients in it. Neither you nor our site will know what you are taking. Are you OK with this?

      Have you ever participated in a research study?

      Did you take study medication?

      YES to both: What month and year did you participate? What was the date of your last study visit? What was the study for? Where did you participate?

      What city do you live in?

      We are in Oceanside, CA, and open Monday-Thursday from 8:30 a.m. to 6:00 p.m. Will it be a problem to make visits on a weekly or biweekly basis?

      What is your height and weight?

      What is your date of birth?

      How did you hear about us?

      Have you ever seen a psychiatrist?

      If YES: What psychiatric diagnosis were you given? When?

      Have you ever been given any other diagnosis?

      Do you currently take, or have you ever taken any psychiatric medications?

      If yes, what are they for? List medication, dose, start date, and end date for current and past psychiatric medications:

      You may be required to discontinue some or all your current medications if you wish to participate in a research study. Are you willing to stop them, including psychiatric medications, if necessary?

      Here is a list of medical problems, please let me know if you have had or have any of the following medical conditions: Any history of diseases, Arthritis, Cardiovascular Disease or Heart Disease, Irregular Heart Rate or Arrhythmia, Diabetes, Hepatitis A, B, or C, Human Immunodeficiency Virus (HIV), High Blood Pressure, High Cholesterol, Eating Disorder, Sleep Apnea, or other condition:

      DO YOU TAKE ANY MEDICATIONS FOR ANY MEDICAL CONDITIONS?

      If yes, what medical condition and what medications are you currently taking?

      Have you EVER had a seizure, stroke, or head injury (leaving you unconscious for more than a few minutes)?

      If yes, date/details of event:

      Have you ever had cancer? If YES: What type of cancer? Date of diagnosis: Date last scan/other negative lab result:

      Do you currently take any pain medication for ANY REASON?

      If yes, what is the name and dose of the medication? How often do you take it? What type of pain is it for? When was your last dose? Are any changes in dosage expected anytime soon?

      (Females only) Are you currently pregnant/nursing/trying to get pregnant?

      If no, are you on any form of birth control? (If not) Are you sexually active and willing to use one or two forms of contraception for a study? (If yes) What forms are you willing to use?

      Do you have any MEDICATION ALLERGIES/SENSITIVITIES?

      If yes, what medications? What happens to you when you take it?

      Have you had any recent or planned surgeries or history of gastric bypass surgery?

      If YES: What did you/will you have surgery for? When was/is the surgery?

      Do you have a history of, or currently have a Substance Abuse/Alcohol Abuse problem?

      If Yes, when? How long have you been sober? What substance(s)? Do you drink? If so, how much and how often?

      Do you currently use, or have you ever used, any drugs like meth, cocaine or recreational or medical marijuana, even occasionally?

      If YES, How often? When was your last use?

      A negative urine drug screen is required prior to screening for most studies.

      I accept

      Have you ever been hospitalized overnight for any psychiatric reasons (suicide attempts, etc.)?

      If YES: When (month and year)? How long were you hospitalized?

      Where?

      What were you hospitalized for?

      Any other overnight hospitalizations?

      Do you have a history of any suicide attempts or ideation (thoughts of suicide)?

      If YES: How many times did you attempt? When did you attempt? How did you attempt each time?

      Have you ever had any TMS treatments or shock therapy? (Electroconvulsive therapy -ECT)?

      Have you ever had thoughts of harming others?

      If YES, what kind of thought did you have? When was the last time?

      Any additional notes or comments?

      *Required

      https://excellresearch.com/wp-content/uploads/2023/07/Excell-Logo-New-Outlines@2x-1.png
      https://excellresearch.com/wp-content/uploads/2023/08/qtq80-VpnKce.jpeg

      Pre-screening questionnaire and your privacy

      Please be advised that by filling out the study pre-screening questionnaire, you will be asked to provide personal information, including age, gender, and your current medical condition. One of our staff will then reach out to conduct a phone-screen to see if you qualify for one of our current studies at our office location in Oceanside, CA. Your privacy is of the utmost importance to Excell Research. Your privacy will be protected and the information you provide will only be shared with those involved with the clinical research study if it is determined that you may be eligible to participate, unless you permit us to do so or except as required by law. Your information will not be sold to outside companies, nor will it be stored or collected without your direct consent.

      Many pharmaceutical companies and Excell Research are conducting these studies under the Food and Drug Administration (FDA) to learn more about new investigational drugs or treatments. Read our privacy policy to learn more about how your information will be kept private.